Cell and gene therapies are revolutionizing healthcare, offering promising solutions from curative treatments to long-term remission rates. As these treatments enter the market, ensuring fair access while addressing coverage and payment complexities becomes paramount.

  Introducing the inaugural Cell & Gene Therapy Pricing & Reimbursement Summit. Biotech, pharma, physicians, healthcare providers, and regulatory and government agencies will unite to address key issues such as the impact of regulatory acts, implementing pricing models, and collaborating on enhanced reimbursement strategies, aiming to expedite the availability of these advanced therapies to patients.

With the recent approval of Casgevy by Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia by bluebird bio; significant strides in healthcare have been made, offering groundbreaking treatments with transformative potential, yet presenting substantial cost challenges. The Inflation Reduction Act and new Cell and Gene Therapy (CGT) Access Model aim to address these cost concerns by proposing innovative pricing models and reimbursement strategies to ensure affordability and widespread access to these life-changing therapies.

 Join us this June to discuss the impacts of this legislation and together, we will optimize patient access and propel the success of commercial cell and gene therapy launches.

See the full agenda here: https://ter.li/d1rn7b